Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 4/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19332395 | 0.87 | ULK1 (0.50) | ULK1CYP1A2XDHMAPK1ALPL | |
| SCHEMBL23049802 | 0.87 | ULK1 (0.45) | ULK1CYP1A2XDHMAPK1ALPL | |
| SCHEMBL20505161 | 0.80 | ULK1 (0.47) | ULK1CYP1A2XDHALPLPARP1 | |
| SCHEMBL23049733 | 0.78 | ULK1 (0.51) | ULK1CYP1A2XDHMAPK1ALPL | |
| SCHEMBL22647484 | 0.78 | CYP1A2 (0.46) | ULK1CYP1A2XDHMAPK1ALPL | |
| SCHEMBL26372693 | 0.77 | ULK1 (0.47) | ULK1CYP1A2XDHMAPK1ALPL | |
| SCHEMBL11965473 | 0.77 | CYP1A2 (0.45) | ULK1CYP1A2XDHMEN1KMT2A | |
| SCHEMBL29897794 | 0.76 | ULK1 (0.49) | ULK1CYP1A2XDHALPLPARP1 | |
| SCHEMBL4276853 | 0.76 | ULK1 (0.49) | ULK1CYP1A2XDHALPLPARP1 | |
| SCHEMBL11965472 | 0.76 | GAA (0.47) | ULK1CYP1A2XDHMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024126453-A1 | NEW SUBSTITUTED INDOLE-2-CARBOXAMIDES AS PHGDH INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-06-20 | — | — | WO | disclosed |
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-19 | — | — | US | disclosed |
| US-20220008386-A1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-13 | — | — | US | disclosed |
| EP-3596064-B1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | PHGDH, G6PD, PHPT1 | ULK1 2875/4885CYP1A2 1427/4885XDH 334/4885 |
| US-20220008386-A1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | PHGDH, G6PD, PHPT1 | ULK1 2875/4885CYP1A2 1427/4885XDH 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.